• Richard L. Greenman


In addition to a number of viruses, toxins and drugs can cause injury to the liver. Ethanol is perhaps the most common example of a toxin/drug etiology of hepatitis. This chapter will, however, deal exclusively with the viral etiologies of hepatitis, the epidemiology of these agents, and clinical strategies for prevention of disease.


Acute Hepatitis Yellow Fever Virus Posttransfusion Hepatitis Chlorine Residual Intravenous Drug Abuser 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Feinstone, S. M., Kapikian, A. Z., and Purcell, R. H.: Hepatitis A: Detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 182: 1026, 1973.PubMedCrossRefGoogle Scholar
  2. 2.
    Provost, P. J., and Hilleman, M. R.: Propagation of human hepatitis A virus in cell culture in vitro. Proc. Soc. Exp. Biol. Med. 160: 213, 1979.PubMedGoogle Scholar
  3. 3.
    Krugman, S., Ward, R., and Giles, J. P.: The natural history of infectious hepatitis. Am. J. Med. 32: 717, 1962.PubMedCrossRefGoogle Scholar
  4. 4.
    Rindge, M. E., Mason, J. O., and Elsea, W. R.: Infectious hepatitis: Report of an outbreak in a small Connecticut school due to water-borne transmission. JAMA 180: 33, 1962.PubMedCrossRefGoogle Scholar
  5. 5.
    Portnoy, B. L., Mackowiak, P. A., Caraway, C. T., et al.: Oyster associated hepatitis: Failure of shellfish certification program to prevent outbreaks. JAMA 233: 1065, 1975.PubMedCrossRefGoogle Scholar
  6. 6.
    Dienstag, J. L., Szmuness, W., Stevens, V. E., et al.: Hepatitis A virus infection: New insights from seroepidemiologic studies. J. Infect. Dis. 137: 328, 1978.PubMedCrossRefGoogle Scholar
  7. 7.
    Dienstag, J. L., Feinstone, S. M., Kapikian, A. Z., et al.: Fecal shedding of hepatitis A antigen. Lancet 1: 765, 1975.PubMedCrossRefGoogle Scholar
  8. 8.
    Mosley, J. W., Reiser, D. M., Braholl, D., et al.: Comparison of two lots of immune serum globulin for prophylaxis of infectious hepatitis. Am. J. Epidemiol. 85: 539, 1968.Google Scholar
  9. 9.
    Robinson, W. S.: Genetic variation among hepatitis B and related viruses. Ann. NY Acad. Sci. 354: 371, 1980.PubMedCrossRefGoogle Scholar
  10. 10.
    Robinson, W. S.: Hepatitis B virus and the delta agent, in Mandell G. L., Douglas, R. G., Jr., and Bennet, J. E. (eds.): Principles and Practice of Infectious Diseases, 2nd ed. Wiley, New York, 1985, p. 1002.Google Scholar
  11. 11.
    Szmuness, W.: Hepatocellular carcinoma and the hepatitis B virus: Evidence for a causal association. Prog. Med. Virol. 24: 40, 1978.PubMedGoogle Scholar
  12. 12.
    Centers for Disease Control: Inactivated hepatitis B virus vaccine. Morbid. Mortal. Wkly. Rep. 31: 318, 1982.Google Scholar
  13. 13.
    Cherubin, C. E., Purcell, R. H., Landers, J. J., et al.: Acquisition of antibody to hepatitis B antigen in three socioeconomically different medical populations. Lancet 2: 149, 1972.PubMedCrossRefGoogle Scholar
  14. 14.
    Alter, J. H., Purcell, R. H., and Gerin, J. L.: Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen. Infect. Immun. 16: 928, 1977.PubMedGoogle Scholar
  15. 15.
    Okada, K., Kainiyama, I., Inometa, M., et al.: e Antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus in their infants. N. Engl. J. Med. 294: 746, 1976.PubMedCrossRefGoogle Scholar
  16. 16.
    Hoofnagle, J. H., Seef, L. B., Bales, Z. B., et al.: The Veterans Administration Hepatitis Cooperative Study Group. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N. Engl. J. Med. 298: 1379, 1978.PubMedCrossRefGoogle Scholar
  17. 17.
    Alter, H. S., Holland, P. V., and Purcell, R. H.: The emerging pattern of post-transfusion hepatitis. Am. J. Med. Sci. 270: 329, 1975.PubMedCrossRefGoogle Scholar
  18. 18.
    Perspectives on control of viral hepatitis type B. Morbid. Mortal. Wkly. Rep. 25(suppl. 1, no. 17): 3, 1976.Google Scholar
  19. 19.
    Szmuness, W., Stevens, C. E., Harley, E. J., et al.: Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N. Engl. J. Med. 303: 833, 1980.PubMedCrossRefGoogle Scholar
  20. 20.
    Seef, L. B., Wright, E. C., Zimmerman, H. J., et al.: Type B hepatitis after needlestick exposure: Prevention with hepatitis B immunoglobulin. A final report of the Veterans Administration Cooperative Study. Ann. Intern. Med. 88: 285, 1978.Google Scholar
  21. 21.
    Grady, G. F., Lee, V. A., Prince, A. M., et al.: Hepatitis B immune globulin for accidental exposures among medical personnel. Final report of a multi-center controlled trial. J. Infect. Dis. 137: 131, 1978.PubMedCrossRefGoogle Scholar
  22. 22.
    Beasley, R. P., Trepo, C., Stevens, C. E., et al.: The e antigen and vertical transmission of hepatitis B surface antigen. Am. J. Epidemiol. 105: 94, 1977.PubMedGoogle Scholar
  23. 23.
    Beasley, R. P., Hwang, L. Y., Lin, C. C., et al.: Hepatitis B immunoglobulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B carrier state. Lancet 2: 388, 1981.PubMedCrossRefGoogle Scholar
  24. 24.
    Beasley, R. P., Hwang, L. Y., Lin, C. C., et al.: Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2: 1099, 1983.PubMedCrossRefGoogle Scholar
  25. 25.
    Rizetto, M., Hoyer, B., Canese, M. G., et al.: Delta agent: The association of delta antigen with hepatitis B surface antigen and ribonucleic acid in the serum of delta-infected chimpanzees. Proc. Natl. Acad. Sci. USA 77: 6124, 1980.CrossRefGoogle Scholar
  26. 26.
    Rizetto, M., Purcell, R. H., and Gerin, J. L.: Epidemiology of HBV-associated delta agent: Geographical distribution of anti-delta and prevalence in polytransfused HBgAg carriers. Lancet 1: 1215, 1980.CrossRefGoogle Scholar
  27. 27.
    Nicholson, K. G.: Hepatitis delta infections. Br. Med. J. 290: 1370, 1985.CrossRefGoogle Scholar
  28. 28.
    Tabor, E.: The three viruses of non-A non-B hepatitis. Lancet 1: 743, 1985.PubMedCrossRefGoogle Scholar
  29. 29.
    Brotman, B., Prince, A. M., and Huima, T.: Non-A, non-B hepatitis: Is there more than a single blood-borne strain? J. Infect. Dis. 151: 618, 1985.PubMedCrossRefGoogle Scholar
  30. 30.
    Seto, B., Coleman, W. G., Iwarson, S., et al.: Detection of reverse transcriptase activity in association with the non-A, non-B hepatitis agent(s). Lancet 2: 941, 1984.PubMedCrossRefGoogle Scholar
  31. 31.
    Aach, R. D., Szmuness, W., Mosley, J. W., et al.: Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis. N. Engl. J. Med. 204: 989, 1981.CrossRefGoogle Scholar
  32. 32.
    Alter, J. H., Purcell, R. H., Holland, P. V., et al.: Donor transaminase and recipient hepatitis: Impact on blood transfusion service. JAMA 246: 630, 1981.PubMedCrossRefGoogle Scholar
  33. 33.
    Seeff, C. B., and Hoofnagle, J. H.: Immunoprophylaxis of viral hepatitis. Gastroenterology 77: 161, 1979.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • Richard L. Greenman
    • 1
  1. 1.Department of Medicine, Division of Infectious DiseasesUniversity of Miami School of Medicine, and Miami Veterans Administration Medical CenterMiamiUSA

Personalised recommendations